Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in first-line metastatic or locally advanced adrenocortical carcinoma
NCT01514526Phase 2Completed
- Sponsor
- SOGUG
- Start
- Jan 2012
- Primary completion
- Jul 2013
- Countries
- 1
01
Overview
A Phase 2 trial of dovitinib in adrenocortical carcinoma (ACC), sponsored by SOGUG. Started Jan 2012; status: completed.
02
Drugs
dovitinib
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT01514526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514526.